PORTLAND, Ore., Nov. 8 /PRNewswire/ --
Bioject Medical Technologies Inc. (Nasdaq: BJCT), a leading developer of
needle-free drug delivery systems, today announced a special shareholder
meeting to approve the issuance of common stock to fund the redemption of the
Company's outstanding Series A Preferred Stock. Proxy materials, including
the proxy card solicited by management, were mailed to shareholders on or
before November 5, 2001. Due to the short time period between mailing of the
proxy materials and the special meeting date, shareholders are urged to vote
their shares promptly by signing and returning their proxy card as soon as
possible or voting via phone or Internet.
WHEN: November 20, 2001
9:00 am Pacific Standard Time
WHERE: 7620 SW Bridgeport Rd.
Portland, OR 97224
Bioject Medical Technologies Inc., based in Portland, Oregon, is an
innovative developer and manufacturer of needle-free drug delivery systems.
Needle-free injection works by forcing medication at high speed through a tiny
orifice held against the skin. This creates a fine stream of high-pressure
fluid penetrating the skin and depositing medication in the tissue beneath.
The company is focused on developing mutually beneficial agreements with
leading pharmaceutical and biotechnology companies. Bioject's partners now
include Amgen, Serono and Alkermes.
More information can be found at Bioject's home page at:
http://www.bioject.com/ .
SOURCE Bioject Medical Technologies Inc.
 back to top
Related links:
http://www.bioject.com
CONTACT:
Cecelia Heer, Investor Relations Manager of
Bioject Medical Technologies Inc., +1-503-639-7221, ext. 556; or
IR/Media, Jim Flanagan of IR Strategic Advisors, +1-781-863-1333,
or jflanagan@iradvisors.com, for Bioject Medical Technologies
Inc.
|
